Guerbet announces first patient dosing with Elucirem for contrast-enhanced MRI


guerbetGuerbet has shared in a press release that it has commercially launched Elucirem (gadopiclenol) and the first patient has received a dosing. This is following US Food and Drug Administration (FDA) approval in 2022. The first dosing took place at the Hospital of the University of Pennsylvania (Philadelphia, USA).

“Having the ability to use a lower dose of gadolinium, while seeing the diagnostic value and good tolerance during the magnetic resonance imaging [MRI] would be a significant improvement for the practice of neuroradiology,” said Laurie A Loevner, Division Chief, Neuroradiology and Professor of Radiology at the Perelman School of Medicine, University of Pennsylvania.


Please enter your comment!
Please enter your name here